Viridian Therapeutics (VRDN) Earnings Date, Estimates & Call Transcripts $18.54 +0.10 (+0.54%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$18.58 +0.05 (+0.24%) As of 08/15/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Viridian Therapeutics Earnings Summary Viridian Therapeutics released Q2 2025 earnings on August 6, 2025, reporting an EPS of -$1.00, which met the consensus estimate of -$1.00. Quarterly revenue rose 4.2% year-over-year to $0.08 million, above analysts' expectations of $0.05 million. With a trailing EPS of -$3.83, Viridian Therapeutics' earnings are expected to decrease next year, from ($4.03) to ($4.31) per share. Latest Q2 Earnings DateAug. 6EstimatedConsensus EPS (Aug. 6) -$1.00 Actual EPS (Aug. 6) -$1.00 Actual Revenue (Aug. 6) $0.08MQ2 2025 Earnings ResourcesQ2 2025 Earnings Report Quarterly Report (10-Q) Press Release (8-K) Slide DeckSlide DeckFull Screen Slide DeckPowered by Get Viridian Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataVRDN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.VRDN Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Viridian Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20254-$1.09-$0.81-$0.97Q2 20254-$1.09-$0.82-$0.98Q3 20255-$1.03-$0.13-$0.69Q4 20255-$1.29-$0.83-$1.09 FY 2025 18 -$4.50 -$2.59 -$3.72 Q1 20262-$1.20-$0.85-$1.03Q2 20262-$1.26-$0.88-$1.07Q3 20262-$1.23-$0.87-$1.05Q4 20262-$1.29-$0.66-$0.98 Viridian Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025-$1.00-$1.00--$1.00$0.05M$0.08M5/6/2025Q1 2025-$0.95-$0.87+$0.08-$0.87$0.16M$0.07M2/27/2025Q4 2024-$1.05-$0.81+$0.24-$0.81$0.05M$0.07M11/12/2024--$1.11-$1.15 -$0.04-$1.15$0.08M$0.09M8/8/2024--$0.87-$1.02 -$0.15-$1.02$0.09M$0.07M5/8/2024Q1 2024-$1.07-$0.79+$0.28-$0.79$0.09M$0.07M2/27/2024Q4 2023-$0.98-$1.35 -$0.37-$1.35$0.15M$0.07M11/13/2023Q3 2023-$1.22-$1.09+$0.13-$1.09$0.28M$0.07M Viridian Therapeutics Earnings - Frequently Asked Questions When did Viridian Therapeutics announce their last quarterly earnings? Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earning data on Wednesday, August 6, 2025. Learn more on VRDN's earnings history. Did Viridian Therapeutics beat their earnings estimates last quarter? In the previous quarter, Viridian Therapeutics (NASDAQ:VRDN) reported ($1.00) earnings per share (EPS) to hit the analysts' consensus estimate of ($1.00). Learn more on analysts' earnings estimate vs. VRDN's actual earnings. How much revenue does Viridian Therapeutics generate each year? Viridian Therapeutics (NASDAQ:VRDN) has a recorded annual revenue of $300,000.00. How much profit does Viridian Therapeutics generate each year? Viridian Therapeutics (NASDAQ:VRDN) has a recorded net income of -$269.95 million. VRDN has generated -$3.83 earnings per share over the last four quarters. What is Viridian Therapeutics' EPS forecast for next year? Viridian Therapeutics' earnings are expected to decrease from ($4.03) per share to ($4.31) per share in the next year. More Earnings Resources from MarketBeat Related Companies Option Care Health Earnings RadNet Earnings Sotera Health Earnings BrightSpring Health Services Earnings Surgery Partners Earnings GeneDx Earnings Concentra Group Holdings Parent Earnings Privia Health Group Earnings Veracyte Earnings Addus HomeCare Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Green Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move Higher This page (NASDAQ:VRDN) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access